IPO Timeline
Broker Results (T-2)
2022-06-20
Some brokers release in afternoon
Grey Market (T-1)
2022-06-21
Afternoon
HKEX Allotment (T-1)
2022-06-21
Evening
Registrar Allotment (T-1)
2022-06-21
Evening
Listing Day (T)
2022-06-22
First day of trading
Company Overview
| Stock Name | 美因基因有限公司 |
|---|---|
| Stock Code | 06667 |
| Company Full Name | 美因基因有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國提供消費級基因檢測及癌癥篩查服務。 |
| Listing Date | 2022-06-22 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市海淀區花園北路健康智谷401 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.megagenomics.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 18.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 81.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 21,531,600 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 18.0 |
|---|---|
| First Day Open | HK$ 19.48 |
| First Day Change | -61.39% |
| First Day Volume | 3858800.0 |
| First Day Turnover | 74244600.0 |
Use of Proceeds
| Use of Proceeds | 1、約30%或46.0百萬港元將用于我們的消費級基因檢測及癌癥篩查服務及產品的銷售、營銷及商業化； 2、約25%或38.4百萬港元將投資于研發我們的服務及產品； 3、約20%或30.7百萬港元將用于增加或擴大我們的檢測能力及產能； 4、約15%或23.0百萬港元將用于通過投資或收購具吸引力的技術或檢測相關公司，為我們在整個行業價值鏈的擴張提供資金； 5、約10%或15.3百萬港元預期將用作營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中信建投（国际）融资有限公司 CE BAU112
Overall Coordinators (3)
中信建投（国际）融资有限公司 CE BAU112
招商证券（香港）有限公司 CE AAI650
中泰国际证券有限公司 CE BAA855
Joint Bookrunners (7)
中信建投（国际）融资有限公司 CE BAU112
招商证券（香港）有限公司 CE AAI650
中泰国际证券有限公司 CE BAA855
富途证券国际（香港）有限公司 CE AZT137
老虎证券（香港）环球有限公司 CE BMU940
利弗莫尔证券有限公司 CE BJN764
国泰君安证券（香港）有限公司 CE ABY236
Joint Lead Managers (7)
中信建投（国际）融资有限公司 CE BAU112
招商证券（香港）有限公司 CE AAI650
中泰国际证券有限公司 CE BAA855
富途证券国际（香港）有限公司 CE AZT137
老虎证券（香港）环球有限公司 CE BMU940
利弗莫尔证券有限公司 CE BJN764
国泰君安证券（香港）有限公司 CE ABY236
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 迈克生物股份有限公司 | 58,158,000 HKD | — | 27.01% | — | 6 months | 2022-12-22 |
| 2 | 南昌工控园区股权投资合伙企业(有限合伙) | 81,414,000 HKD | — | 37.81% | — | 6 months | 2022-12-22 |
| 3 | 南昌金融控股有限公司 | 34,898,400 HKD | — | 16.21% | — | 6 months | 2022-12-22 |
Directors & Management
| Chairman | 林琳 |
|---|---|
| Company Secretary | 吳嘉智 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 美年大健康產業控股股份有限公司(15.57%);俞熔(9.53%);郭美玲(9.2%);天津世紀宇能企業管理合伙企業(有限合伙)(5.06%) |
|---|
IPO Timeline
